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Background: Survival after dementia diagnosis varies considerably. Previous studies were focused mainly on factors
related to demographics and comorbidity rather than on Alzheimer’s disease (AD)-related determinants. We set out
to answer the question whether markers with proven diagnostic value also have prognostic value. We aimed to
identify disease-related determinants associated with mortality in patients with AD.
Methods: We included 616 patients (50% female; age 67 ± 8 years; mean Mini Mental State Examination score 22
± 3) with dementia due to AD from the Amsterdam Dementia Cohort. Information on mortality was obtained from
the Dutch Municipal Register. We used age- and sex-adjusted Cox proportional hazards analysis to study associations of
baseline demographics, comorbidity, neuropsychology, magnetic resonance imaging (MRI) (medial temporal lobe, global
cortical and parietal atrophy, and measures of small vessel disease), and cerebrospinal fluid (CSF) (β-amyloid 1–42, total
tau, and tau phosphorylated at threonine 181 [p-tau]) with mortality (outcome). In addition, we built a multivariate
model using forward selection.
Results: After an average of 4.9 ± 2.0 years, 213 (35%) patients had died. Age- and sex-adjusted Cox models showed
that older age (HR 1.29 [95% CI 1.12–1.48]), male sex (HR 1.60 [95% CI 1.22–2.11]), worse scores on cognitive functioning
(HR 1.14 [95% CI 1.01-1.30] to 1.31 [95% CI 1.13–1.52]), and more global and hippocampal atrophy on MRI (HR 1.18 [95%
CI 1.01-1.37] and HR 1.18 [95% CI 1.02-1.37]) were associated with increased risk of mortality. There were no associations
with comorbidity, level of activities of daily living, apolipoprotein E (APOE) ε4 status, or duration of disease. Using forward
selection, the multivariate model included a panel of age, sex, cognitive tests, atrophy of the medial temporal lobe, and
CSF p-tau.
Conclusions: In this relatively young sample of patients with AD, disease-related determinants were associated with an
increased risk of mortality, whereas neither comorbidity nor APOE genotype had any prognostic value.
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Dementia due to Alzheimer’s disease (AD) is, by defin-
ition, a progressive disorder [1]. For patients, a diagnosis
is not the endpoint, but rather the beginning of the subse-
quent trajectory of disease. Physicians are fairly good at
establishing an accurate diagnosis, but they are hardly able* Correspondence: h.rhodius@vumc.nl
1Alzheimer Center, Department of Neurology, VU University Medical Center,
Amsterdam Neuroscience, P.O. Box 7057, 1007, MB, Amsterdam, The
Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeto predict the course of the disease for the individual pa-
tient. In general, patients with dementia due to AD have a
shorter life expectancy than the general population, with
average survival being between 5 and 10 years [2–4]. Yet,
survival time varies considerably between individuals.
Determinants of mortality in AD have been examined in
various studies. Most have been focused on demographic
factors or on clinical factors such as severity of cognitive
impairment, dependency, and comorbidity [5–9]. Male
sex and older age have been associated with increased risk
of mortality in AD [2, 3, 10]. Cardiovascular diseases andle is distributed under the terms of the Creative Commons Attribution 4.0
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have been identified as determinants of mortality, but only
in studies of older patients with dementia [11–15]. Few
studies have been focused on AD-specific factors, such as
cerebrospinal fluid (CSF) and magnetic resonance imaging
(MRI) markers. More severe neuronal degeneration, as
reflected by a high total tau (tau) concentration and
whole-brain atrophy, has been suggested as a determinant
of mortality [12, 16–18]. In one study, microbleeds were
associated with mortality in AD, and white matter hyper-
intensities (WMH) were associated with mortality in all-
cause dementia [12].
Researchers in previous studies tended to evaluate only
a few prognostic factors per study and included mainly
patients aged 75 years and older, who are at risk of mor-
tality owing to their advanced age even without a
dementia diagnosis [3, 19]. Prognostic factors may be
different for patients with early-onset AD, who are youn-
ger and have less comorbidity but are prone to a more
aggressive disease course [10, 20–22]. We aimed to in-
vestigate the prognostic value of baseline clinical data,
including demographics, comorbidity, neuropsychology,
and CSF and MRI biomarkers, as determinants of mor-
tality in dementia due to AD.
Methods
Patients
In this longitudinal study, we included 616 patients with a
baseline diagnosis of dementia due to AD from a memory
clinic-based cohort (the Amsterdam Dementia Cohort)
who had a baseline visit between 2000 and 2014 [23]. Sub-
jects were selected if a neuropsychological test battery was
available at baseline, with a baseline Mini Mental State
Examination (MMSE) score ≥ 16 and a minimum follow-
up of 2 years. At baseline, patients received a standardized
and multidisciplinary workup, including medical history;
physical, neurological, and neuropsychological examina-
tions; MRI; laboratory tests; and lumbar puncture for CSF
measurements. Years of education and self-reported dur-
ation of complaints were recorded. For the assessment of
activities of daily living, we used the Disability Assessment
for Dementia (DAD) [24]. We included all data that were
collected within 6 months of baseline diagnosis. Diagnoses
were made in a multidisciplinary consensus meeting. Pa-
tients were diagnosed with probable AD using the criteria
of the National Institute of Neurological and Communica-
tive Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association; all patients also met the core clin-
ical criteria of the National Institute on Aging-Alzheimer’s
Association for AD dementia [25, 26].
Medical history
We recorded and defined the presence (yes/no) of
hypertension (history of hypertension and/or use ofantihypertensive drugs), hypercholesterolemia (history
of hypercholesterolemia and/or use of cholesterol-
lowering drugs), diabetes (history of diabetes mellitus
and/or use of antidiabetic drugs), and cardiovascular
disease (at least one of the following: history of coron-
ary heart disease, heart failure, heart disease, peripheral
vascular disease, stroke, and/or transient ischemic
attack). Furthermore, we dichotomized smoking status
(never smoked versus current or history of smoking)
and counted the medications used per patient.Neuropsychological tests
Cognitive function was assessed at baseline with a stan-
dardized test battery in which the MMSE was used for
global cognitive functioning [27]. For memory, the
Visual Association Test (VAT) and the Rey Auditory
Verbal Learning Task (RAVLT) were included [28, 29].
To measure mental speed and attention, we used Trail
Making Test A (TMT-A) and the forward condition of
the digit span. Trail Making Test B (TMT-B) and the
backward condition of the digit span were used for ex-
ecutive functioning [30, 31]. Language and executive
functioning were tested by category fluency (animals)
[32]. Missing data ranged from n = 19 (3%) (digit span
forward) to n = 67 (11%) (RAVLT, delayed recall).MRI
Subjects were scanned as part of clinical workup
using a standardized protocol on a 1.0-, 1.5-, or 3.0-T
system. All scans were visually rated by trained raters
and subsequently evaluated in a consensus meeting
with an experienced neuroradiologist [23]. Visual
rating of medial temporal lobe atrophy (MTA) was
performed using coronal T1-weighted images on a 5-
point (0–4) scale from the average score of the left
and right sides [33]. Global cortical atrophy (GCA)
was assessed visually on axial fluid-attenuated inver-
sion recovery (FLAIR) images (range of scores 0–3)
[34]. Parietal atrophy was rated using T1-weighted
and FLAIR weighted images viewed in sagittal, axial,
and coronal planes by computing an average score of
the left and right sides (range 0–3) [35]. WMH were
rated on axial FLAIR images using a four-step scale
(range 0–3) [36]. Lacunes were defined as deep
lesions (3–15 mm) with CSF-like signals on all se-
quences and were dichotomized as present or absent.
Microbleeds were defined as small, round foci of
hypointense signal up to 10 mm in brain parenchyma
on T2*-weighted gradient echo images. The total
number of microbleeds was counted and divided into
three categories: zero, one or two, and three or more
microbleeds. MRI data were available for 485 (79%)
subjects.
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CSF analyses were performed at the Neurochemistry
Laboratory at the Department of Clinical Chemistry of
the VUmc. CSF was obtained by lumbar puncture be-
tween the L3-L4 or L4-L5 intervertebral space by using
a 25-gauge needle and collected into polypropylene
tubes. Within 2 h, the CSF was centrifuged at 1800 × g
for 10 minutes at 4 °C, transferred to new polypropylene
tubes, and stored at −20 °C until biomarker analysis
(within 2 months). β-Amyloid 1–42 (Aβ42), tau, and tau
phosphorylated at threonine 181 (p-tau) were measured
with commercially available enzyme-linked immuno-
sorbent assays (Innotest; Fujirebio, Ghent, Belgium) [37].
CSF data were available for 466 (76%) subjects.
APOE genotyping
DNA was isolated from 10 ml of ethylenediaminetetraace-
tic acid blood. Apolipoprotein E (APOE) genotype was de-
termined using the LightCycler APOE mutation detection
method (Roche Diagnostics GmbH, Mannheim, Germany).
According to APOE ε4 allele status, patients were dichoto-
mized into carriers (hetero- and homozygous) and noncar-
riers. APOE status was available for 562 (91%) subjects.
Outcome measure
For each patient, we obtained information on all-cause
mortality (died yes/no with a date of death) from the
Dutch municipal population register. This register was
searched on 19 October 2016. Causes of death cannot be
determined from this municipal registry. We definedTable 1 Baseline characteristics of patients with Alzheimer’s disease
No. of patients
Demographics
Female sex, n (%) 616
Age, years 616
APOE ε4 carrier, n (%) 562
Years of education 616
Years of complaints 611
Years to outcome 616
Activities of daily living (DAD) 372
Medical history
Smoking, n (%) 599
Hypertension, n (%) 616
Hypercholesterolemia, n (%) 616
Diabetes mellitus, n (%) 616
Cardiovascular disease, n (%) 616
No. of medications 616
Abbreviations: APOE Apolipoprotein E, DAD Disability Assessment for Dementia (ran
Years to outcome: in case of alive, follow-up duration; in case of died, duration to d
Data are presented as mean ± SD unless otherwise specified. Group differences we
variables, the chi-square test was usedfollow-up duration as the time between the date of
baseline AD diagnosis and the date of death or, if
alive, between the date of baseline AD diagnosis and
19 October 2016.
Statistical analyses
Statistical analyses were performed using IBM SPSS
Statistics version 22 software (IBM, Armonk, NY,
USA). p < 0.05 was considered significant. Baseline
characteristics were compared using parametric and
nonparametric tests when appropriate. We used pat-
tern analysis to explore the amount and randomness
of missing data. Because missing data were at ran-
dom, but not completely at random, we imputed all
missing data imputed using multiple imputation, in
which the missing values were estimated on the basis
of other available baseline variables in 15 imputation
cycles.
To allow comparison of results on different tests
within patients, all continuous variables were standard-
ized to z-scores. All neuropsychological tests, except
TMT-A and TMT-B, as well as CSF Aβ42, were inverted
by computing −1 × z-score, with the result being that a
higher score implied more advanced disease. We used
Cox proportional hazards models to assess associations
between all baseline determinants and mortality, taking
into account time to death, using the pooled results of
the 15 imputations. Each measure was assessed un-
adjusted (model 1), adjusted for age and sex (model 2),
and adjusted additionally for MMSE and duration ofaccording to outcome
Alive (n = 403) Died (n = 213) p Value
218 (54) 91 (43) 0.007
66 ± 7 69 ± 9 0.000
250 (67) 119 (63) 0.280
11 ± 3 11 ± 3 0.675
3.2 ± 2.6 2.8 ± 2.0 0.066
5.3 ± 1.8 4.3 ± 2.1 0.000
83 ± 17 82 ± 17 0.450
185 (47) 98 (49) 0.640
127 (32) 77 (36) 0.245
103 (26) 46 (22) 0.275
31 (8) 15 (7) 0.770
71 (18) 53 (25) 0.032
2.0 ± 2.0 2.4 ± 2.1 0.062
ge 0–100)
eath
re calculated using Student’s t test for continuous variables. For categorical
Table 2 Disease-specific characteristics at baseline, according to
outcome
No. of
patients
Alive
(n = 403)
Died
(n = 213)
p Value
Cognitive tests
MMSE 616 22 ± 3 22 ± 3 0.480
Digit span forward 597 11 ± 3 11 ± 3 0.908
Digit span backward 593 7 ± 3 6 ± 2 0.154
VAT naming 576 11 ± 1 11 ± 2 0.194
VAT memory 579 6 ± 4 6 ± 4 0.641
TMT-A, seconds 581 81 ± 62 92 ± 64 0.046
TMT-B, seconds 581 299 ± 235 329 ± 215 0.079
RAVLT, immediate recall 551 23 ± 7 22 ± 8 0.026
RAVLT, delayed recall 549 2 ± 2 2 ± 2 0.391
Category fluency 563 13 ± 5 13 ± 6 0.325
MRI
MTA 484 1.2 ± 0.8 1.6 ± 0.9 0.000
PA 470 1.2 ± 0.8 1.3 ± 0.8 0.185
GCA 482 1.0 ± 0.6 1.2 ± 0.7 0.004
WMH 485 1.0 ± 0.8 1.1 ± 0.9 0.152
Lacunes present, n (%) 483 20 (6) 16 (9) 0.262
Microbleeds by category,
n (%)
393 0.064
0 microbleeds 181 (75) 112 (74)
1–2 microbleeds 41 (17) 17 (11)
≥ 3 microbleeds 20 (8) 22 (15)
Infarcts present, n (%) 482 3 (1) 4 (2) 0.257
CSF
Aβ42, pg/ml 466 525 ± 172 490 ± 173 0.037
tau, pg/ml 460 662 ± 340 695 ± 434 0.374
p-tau, pg/ml 463 83 ± 33 91 ± 45 0.031
Abbreviations: MMSE Mini Mental State Examination (score range 0–30), Digit
span forward and backward (range 0–21), VAT Visual Association Test (naming
range 0–12, memory range 0–12), TMT Trail Making Test (no range), RAVLT Rey
Auditory Verbal Learning Task (immediate recall range 0–60, delayed recall
range 0–15), MTA Medial temporal lobe atrophy (range 0–4; average score of
left and right sides), PA Parietal atrophy (range 0–3; average score of left and
right sides), GCA Global cortical atrophy (range 0–3), WMH White matter
hyperintensities (range 0–3), Aβ42 β-Amyloid 1–42, p-tau Tau phosphorylated
at threonine 181, MRI Magnetic resonance imaging, CSF Cerebrospinal fluid
Data are presented as mean ± SD unless otherwise specified. Group differences
were calculated using Student’s t test for continuous variables. For categorical
variables, the chi-square test was used
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fect modification, using interaction terms for each vari-
able with *age and *sex, was not found. Subsequently,
we aimed to select the optimal combination of determi-
nants by constructing a multivariate model using for-
ward selection. The model was built by assessing all
variables and consecutively selecting the variable with
the lowest p value in a stepwise manner until p was <
0.10. In case of several variables with the same lowest p
value, we calculated the Wald statistics and selected the
variable with the highest Wald value. Variables were
added only when the overall model improved, as evalu-
ated using the −2 log-likelihood ratio. In an additional
set of analyses, we performed similar analyses based on
nonimputed data, and the results were comparable (see
Additional file 1: Table S1 and S2). Finally, we created
Kaplan-Meier curves for each of the variables selected
by forward selection. Because all variables except for sex
were continuous values, we used tertiles for the survival
curves. Data are represented as HRs with accompanying
95% CIs.
Results
Table 1 presents the baseline characteristics of the
patients. After a follow-up of 4.9 ± 2.0 years, 213(35%)
patients had died (duration baseline AD diagnosis to
death 4.3 ± 2.1 years) and 403(65%) patients were alive
(follow-up duration 5.3 ± 1.8 years) on the 19th October
2016. Patients who had died were more often male, older
and more often had cardiovascular disease. There was
no difference in self-reported duration of complaints or
years or activities of daily living (as measured with the
DAD.
Patients who had died performed worse at baseline on
TMT-A and RAVLT immediate recall, but MMSE scores
and performance on the other cognitive tests were simi-
lar. In addition, these patients’ biomarkers were indica-
tive of more severe AD pathology, with a higher MTA
and GCA, lower Aβ42, and higher p-tau values (Table 2).
We used Cox proportional hazards models to evaluate
associations between the individual determinants and
mortality, taking into account time to death (Tables 3
and 4). Male sex and older age were associated with an
increased risk of mortality. After adjustment for age and
sex, worse performance on MMSE, digit span backward,
VAT naming, TMT-A, TMT-B, and RAVLT immediate
recall and category fluency were associated with an in-
creased risk of mortality. In addition, more severe MTA
and GCA seen on MRI scans were associated with an in-
creased risk of mortality. Duration of complaints, activ-
ities of daily living (as measured with the DAD), years of
education, APOE ε4 presence, comorbidity, MRI mea-
sures of small vessel disease, and CSF biomarkers were
not associated with mortality. When we adjustedadditionally for MMSE and duration of complaints as a
proxy for disease severity, all related variables from
model 2, except MTA, remained associated with
mortality.
Next, we aimed to identify the optimal combination of
determinants in a multivariate model. With use of for-
ward selection, the model included age (HR 1.31, 95%
CI 1.12–1.54, p = 0.001), male sex (HR 1.67, 95% CI
1.26–2.21, p = 0.000), digit span backward (HR 1.22,
Table 3 Cox proportional hazards models used to evaluate influence of baseline characteristics and medical history on survival
Model 1 unadjusted Model 2 adjusted for age
and sex
Model 3: model 2 plus MMSE
and duration of complaints
HR (95% CI) p value HR (95% CI) p Value HR (95% CI) p Value
Demographics
Male sexa 1.57 (1.20–2.07) 0.001 1.60 (1.22–2.11) 0.001 1.79 (1.35–2.37) 0.000
Age 1.27 (1.11–1.46) 0.001 1.29 (1.12–1.48) 0.000 1.33 (1.15–1.53) 0.000
Years of education 0.99 (0.86–1.13) 0.844 0.97 (0.84–1.11) 0.636 1.0 (0.90–11.9) 0.671
Years of complaints 0.88 (0.76–1.03) 0.107 0.88 (0.76–1.03) 0.103 0.87 (0.74–1.01) 0.060
APOE ε4 carriera 0.79 (0.59–1.06) 0.114 0.81 (0.61–1.09) 0.163 0.81 (0.60–1.09) 0.170
Activities of daily living (DAD)b 1.13 (0.97–1.31) 0.124 1.11 (0.95–1.29) 0.204 1.09 (0.94–1.26) 0.278
Medical history
Smoking presenta 1.18 (0.89–1.55) 0.250 1.09 (0.82–1.45) 0.541 1.12 (0.85–1.49) 0.419
Hypertension presenta 1.24 (0.94–1.64) 0.130 1.11 (0.83–1.49) 0.467 1.10 (0.82–1.47) 0.528
Hypercholesterolemia presenta 0.86 (0.62–1.19) 0.861 0.73 (0.52–1.01) 0.059 0.75 (0.54–1.05) 0.091
Diabetes mellitus presenta 0.72 (0.43–1.22) 0.228 0.62 (0.37–1.06) 0.079 0.65 (0.40–1.05) 0.108
Cardiovascular disease presenta 1.35 (0.99–1.84) 0.060 1.07 (0.77–1.48) 0.700 1.09 (0.78–1.51) 0.625
No. of medications 1.17 (1.03–1.33) 0.017 1.08 (0.95–1.24) 0.251 1.11 (0.97–1.28) 0.125
Abbreviations: APOE Apolipoprotein E, DAD Disability Assessment for Dementia, MMSE Mini Mental State Examination
Data are presented as HR (95% CI) using pooled data of 15 imputations per SD increase for continuous variables or for the presence of the dichotomous variable
for mortality
a Dichotomous variable
b Because a lower score indicates worse performance, these scores were inverted
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CI 1.06–1.41, p = 0.005), MTA (HR 1.18, 95% CI
1.01–1.38, p = 0.038), and CSF p-tau (HR 1.15, 95%
CI 1.00–1.32, p = 0.058). Survival curves for these
variables are shown in Fig. 1. Of note, because < 50%
of our subjects had died, median survival time can
only be estimated from these curves.
Discussion
Our main finding is that despite their relatively young
age, roughly one of three patients with AD had died with
a mean of 5 years after diagnosis. Predisposing factors
for an increased risk of mortality were older age, male
sex, more severe executive dysfunction, presence of
MTA, and higher p-tau in CSF, indicative of more severe
AD pathology. By contrast, duration of complaints, level
of activities of daily living, APOE ε4 status, and comor-
bidity were not related to mortality.
In our relatively young population (average age 67 ± 8
years) derived from a tertiary memory clinic cohort with
mild to moderate dementia (all with MMSE scores > 16;
average MMSE score 22), 35% of the patients had died
within 5 years after receiving their baseline diagnosis.
This mortality rate is considerably higher than that of
the general Dutch population [19]. Previous studies de-
scribed slightly higher mortality rates, but most studies
included patients older than 75 years of age or with
severe dementia with MMSE scores < 20 [38–40]. Only
a few studies have been focused on mortality in youngpatients with AD or less affected patients, showing com-
parable mortality rates [38, 41–43]. Extending these
former studies, we evaluated not only comorbidity but
also focused on disease-specific markers as determinants
of mortality.
In addition to male sex and older age, both of which
are known determinants of mortality in AD and in the
general population, we found executive dysfunction,
MTA, and higher p-tau in CSF, all reflecting more severe
disease, to be determinants of mortality. Self-reported
duration of complaints was not associated with mortal-
ity, indicating that the patients who died had more
aggressive rather than more advanced disease. In line
with this notion, there was hardly any difference at base-
line in the severity of cognitive impairment between
those who died within the study period and those who
remained alive. Previous studies focused on neuropsych-
ology have shown mainly an association with mortality
when assessing decline over time but not at baseline [5,
38, 39]. In our study, we consistently found tests in the
executive domain and, to a lesser degree, memory as de-
terminants of mortality. A potential explanation for this
finding is that subjects with executive dysfunction are at
greater risk of dependency, increasing the risk of compli-
cations. Also, the executive domain seems to be a medi-
ator for other cognitive domains, whereas tests for
delayed recall were already at floor level in many pa-
tients [44]. This latter finding could explain why tests
for delayed recall showed no association with survival.
Table 4 Cox proportional hazards models used to evaluate influence of cognitive performance, magnetic resonance imaging, and
cerebrospinal fluid at baseline on survival
Model 1 unadjusted Model 2 adjusted for age
and sex
Model 3: model 2 plus MMSE
and duration of complaints
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Cognitive tests
MMSEa 1.11 (0.97–1.28) 0.131 1.23 (1.07–1.42) 0.005 1.25 (1.08–1.44) 0.003
Digit span forwarda 1.07 (0.93–1.23) 0.362 1.10 (0.95–1.26) 0.207 1.03 (0.89–1.20) 0.651
Digit span backwarda 1.21 (1.05–1.40) 0.008 1.31 (1.13–1.52) 0.000 1.24 (1.06–1.46) 0.009
VAT naminga 1.15 (1.01–1.31) 0.037 1.14 (1.01–1.30) 0.042 1.11 (0.97–1.27) 0.136
VAT memorya 1.01 (0.88–1.15) 0.937 1.07 (0.93–1.23) 0.360 1.02 (0.88–1.19) 0.790
TMT-A 1.21 (1.07–1.37) 0.003 1.29 (1.14–1.47) 0.000 1.23 (1.08–1.41) 0.003
TMT-B 1.19 (1.05–1.35) 0.006 1.28 (1.13–1.45) 0.000 1.21 (1.06–1.40) 0.005
RAVLT, immediate recalla 1.23 (1.06–1.43) 0.008 1.19 (1.02–1.38) 0.025 1.11 (0.95–1.30) 0.193
RAVLT, delayed recalla 0.96 (0.84–1.10) 0.533 0.96 (0.83–1.10) 0.507 0.90 (0.78–1.04) 0.154
Category fluencya 1.17 (1.02–1.37) 0.045 1.17 (1.01–1.36) 0.041 1.10 (0.94–1.29) 0.243
MRI
MTA 1.26 (1.10–1.44) 0.001 1.18 (1.02–1.37) 0.030 1.15 (0.98–1.34) 0.081
PA 1.12 (0.97–1.30) 0.113 1.10 (0.95–1.28) 0.192 1.12 (0.96–1.29) 0.143
GCA 1.21 (1.05–1.40) 0.008 1.18 (1.01–1.37) 0.037 1.17 (1.00–1.36) 0.044
WMH 1.16 (1.01–1.33) 0.041 1.07 (0.92–1.25) 0.364 1.05 (0.90–1.22) 0.518
Lacunes presentb 1.15 (0.77–1.71) 0.505 1.10 (0.73–1.66) 0.634 1.17 (0.76–1.79) 0.485
Microbleed categories
Microbleeds, 1–2 0.82 (0.49–1.37) 0.450 0.72 (0.43–1.19) 0.195 0.69 (0.42–1.16) 0.163
Microbleeds, ≥ 3 1.09 (0.80–1.47) 0.598 1.03 (0.76–1.40) 0.840 1.01 (0.74–1.37) 0.956
Infarcts presentb 1.11 (0.63–2.00) 0.710 1.15 (0.64–2.05) 0.641 1.11 (0.60–2.05) 0.727
CSF
Aβ42a 0.98 (0.84–1.14) 0.765 1.02 (0.87–1.18) 0.850 0.99 (0.86–1.16) 0.943
tau 1.05 (0.91–1.22) 0.504 1.09 (0.94–1.27) 0.275 1.07 (0.92–1.26) 0.369
p-tau 1.06 (0.92–1.23) 0.426 1.09 (0.94–1.26) 0.242 1.08 (0.93–1.26) 0.316
Abbreviations: MMSE Mini Mental State Examination, VAT Visual Association Test, TMT Trail Making Test, RAVLT Rey Auditory Verbal Learning Task, MRI Magnetic
resonance imaging, MTA Medial temporal lobe atrophy, PA Parietal atrophy, GCA Global cortical atrophy, WMH White matter hyperintensities score 3, CSF
Cerebrospinal fluid, Aβ42 β-Amyloid 1–42, p-tau Tau phosphorylated at threonine 181
Data are presented as HR (95% CI) using pooled data of 15 imputations per SD increase for continuous variables or for the presence of the dichotomous variable
for mortality
a Because a lower score indicates worse performance, these scores were inverted
b Dichotomous variable
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searchers assessed associations of MRI atrophy markers
with mortality, with findings that global atrophy, but not
MTA, was associated with mortality in dementia [12,
18]. An association of MTA and mortality in AD was
found in a study conducted with computed tomographic
scans [45]. In our univariate models, we found more se-
vere MTA and global atrophy associated with increased
risk of death; in the multivariate forward selection
model, GCA was not included. Atrophy is seen on MRI
scans as a marker of downstream neuronal degeneration
[25]. In this study, other markers of neurodegeneration,
such as p-tau in CSF, were also included in our multi-
variate forward selection model, which confirms theresults of the few studies addressing CSF and mortality
in AD [16, 18]. The effect of WMH seems attributable
largely to age, because the prognostic value disappeared
in the adjusted models. This is different from what has
been found before and could potentially be explained by
the relatively young age of our sample [12].
In line with previous studies, male sex was associated
with higher mortality in AD [3]. It has been suggested
that women present earlier in their disease course owing
to more easily noticed impairment in household tasks,
and hence they have a longer survival time [3]. Also,
women more often lived alone and were more frequently
widowed, leading to impairment being noticed earlier.
We did not find an association with level of activities of
Fig. 1 Kaplan-Meier curve, according to variables from forward selection model: age, sex, TMT-A, digit span backward, MTA, and p-tau (all except
sex stratified in tertiles). Legend: Note: digit span backward: range 0-21, TMT: trail making test (no range), MTA: medial temporal lobe atrophy
ranging 0-4 (average score of left and right side), p-tau: tau phosphorylated at threonine 181. Survival curves were calculated using raw data,
without imputation
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is possibly most relevant in more advanced disease
stages and not in our cohort, where activities of daily liv-
ing were only mildly impaired in most patients [41, 46].
Finally, and contrary to our expectations, we could not
confirm smoking, comorbidity, or number of medica-
tions as predisposing factors for an increased risk of
mortality. Previous studies have shown an association of
cardiovascular risk factors with mortality, but these stud-
ies were focused mostly on older populations that are by
definition at higher risk of both cardiovascular disease
and mortality [11, 13–15, 46]. Also, a higher level of co-
morbidity has previously been shown to relate to sur-
vival time [14, 15], but again in older populations; in our
present study, we used number of medications as a
proxy of level of comorbidity and found no association
[13]. Our study shows that the AD process itself, as
reflected by neuropsychology as well as MRI and CSF
biomarkers, has prognostic value in terms of mortality
as well. This fits with the observation that patients with
AD have higher rates of mortality than the general
population and that AD is the swiftest growing cause of
death in the Western world [2, 19].
Limitations of the present study are that our population
was derived from a tertiary memory clinic, which hampers
the generalizability of the results. However, the added
value of our study is its focus on younger patients, for
whom a paucity of data exists. We studied a broad range
of determinants in patients with a relatively long follow-
up duration. In addition, we included only patients with
MMSE scores ≥ 16 to prevent cognitive testing from being
at floor level. Of note, even in our young, mild to moder-
ately impaired cohort of patients with AD, mortality was
high. Another limitation might be the mean follow-up
duration of 5.3 ± 1.8 years for the patients who remained
alive, implying that these patients might have died shortly
after this period. Nonetheless, all patients had a minimum
follow-up of 2 years. Finally, we had information on medi-
cation use only at baseline and thus had no information
on the prescription of cholinesterase inhibitors after the
diagnosis AD. This could be a limitation because some
studies have shown that cholinesterase inhibitors can in-
crease survival, whereas others have shown no such effect
or only in older patients [41, 43, 47]. Furthermore, we
were not able to look at the relationship between use of
antipsychotics and mortality [48, 49], because only a very
small proportion of our subjects used these medications.
However, use of antipsychotics is likely to occur later in
the course of the disease. Among the strengths of the
present study is our harmonized diagnostic protocol
according to which all patients were assessed, because all
patients were selected from the same memory clinic and
received the same diagnostic workup and similar treat-
ment and management.Conclusions
Our results have important clinical implications. We
found that AD-related factors, rather than comorbidity
or duration of complaints, were associated with in-
creased mortality in our relatively young cohort. This
knowledge enables timely dialogue on prognosis, even in
young patients who are otherwise healthy.
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